Dr. Herbst Discusses the State of Immunotherapy in Lung Cancer

Roy S. Herbst, MD, PhD
Published: Tuesday, Nov 18, 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.

Herbst says immunotherapy is a hope and a partial reality. At this time, about 20-25% of patients treated with immunotherapeutic agents will respond and have a durable response, Herbst says. This provides a real benefit because these patients tend to be the patients that do not usually benefit from EGFR and ALK inhibitors.

Researchers are trying to figure out why the other 75% of lung cancer patients are not responding to immunotherapies, Herbst says. By biopsying tumors, researchers can hopefully understand why immunotherapies do not work in certain patients.

<<< View more from the 2014 Annual Lung Cancer Symposium

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.

Herbst says immunotherapy is a hope and a partial reality. At this time, about 20-25% of patients treated with immunotherapeutic agents will respond and have a durable response, Herbst says. This provides a real benefit because these patients tend to be the patients that do not usually benefit from EGFR and ALK inhibitors.

Researchers are trying to figure out why the other 75% of lung cancer patients are not responding to immunotherapies, Herbst says. By biopsying tumors, researchers can hopefully understand why immunotherapies do not work in certain patients.

<<< View more from the 2014 Annual Lung Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x